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ABSTRACT 
 
Introduction: Diabetes is the most common cause of peripheral nerve involvement. 
Evaluating the effect of antioxidants on diabetic neuropathic pain is important. This study 
aimed at evaluating the effects of Angipars medicine in the treatment of neuropathic 
hyperalgesia in single dose streptozotocin-induced diabetic rats. 
Methods: The study was performed on 50 Spraque dawley rats of 250-300 grams 
weight. The rats were divided into four groups of control, sham, Angipars-receiving 
diabetic, and vehicle-receiving diabetic, with at least 8 rats in each group. Diabetes was 
induced by intraperitoneal injection of 45 mg/kg streptozotocin dissolved in a 0.05 M 
citrate buffer. After confirming the diabetes, the diabetic rats received (5, 10, 20 mg/kg, 
intraperitoneal) Angipars and vehicle for 2 weeks. At the end of the eighth week, the 
control and treated rats were examined through the hot plate and tail flick tests. ANOVA 
was used to evaluate the statistical difference and P<0.05 was considered as significant. 
Results: At the end of the eighth week, the response time to thermal hyperalgesia 
decreased in the vehicle and sham groups compared with the control group. Angipars at 
doses of 5 and 10 mg increased the response time to thermal hyperalgesia compared to the 
vehicle and sham groups in hot plate test. In the tail flick test, 10mg Angipars increased 
the response time to pain similar to the control group. 
Conclusion: This study showed that, as an antioxidant, Angipars is capable of reducing 
neuropathic hyperalgesia in animals with diabetes. 
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Introduction: 
Pain is one of the first signs of illness and the 
most prominent sense among sensory experiences 
through which humans realize their sickness. In 
fact, pain is the most common symptom of a 
disease (1). Experience and research in the past 
decades have shown that novel medicines are 
associated with side effects despite their appropriate 
and undeniable therapeutic impacts (2). 
Consequently, referral to medicinal plants is 
considered again nowadays and many attempts 
were made to use them. 
Diabetes-induced neuropathy is often associated 
with hyperalgesia and allodynia (3). Although many 
studies have reported that neurodegeneration or 
changes in the neurotransmitter system is 
responsible for change in pain perception in patients 
with diabetes (4,5), its exact mechanism is not yet 
known. Some studies have shown that diabetes is 
often associated with chronic neuropathic pain and 
oxidative stress plays an important role in the 
development of many neurological and behavioral 
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changes in diabetic patients (6,7). Therefore, 
evaluation of the effects of antioxidants on pain 
relief in diabetic neuropathy is important. 
Angipars (semelil) is a medicine containing the 
extract of Melilotus officinalis and can improve 
blood flow, reduce inflammation, lead to 
angiogenesis, and decrease diabetic foot ulcers. 
Despite its short production time, many studies 
have investigated the therapeutic effects of this drug 
and most of them were carried out in diabetes-
induced wounds. Accordingly, recent studies have 
suggested that Angipars (semelil) can exert 
therapeutic effect on diabetic foot wounds (8) and 
does not show acute and chronic toxic effects 
(9,11). 
Therefore, based on the mechanisms involved 
in the physiopathology of diabetic neuropathy and 
anti-oxidative and anti-inflammatory effects of 
Angipars, this study investigated its possible effect 
on prevention of neuropathic hyperalgesia in 
diabetic model of rats. 
 
Methods: 
This experimental study was performed on 50 
Spraque dawley rats of 250-300 grams weight. The 
rats were kept at standard conditions of 22±2°C 
temperature and 12-hour periods of light and 
darkness during the course of treatment, except for 
testing, while food and water were freely available. 
The rats were divided into four groups of 
control, sham (diabetic with any compound 
received), Angipars-receiving diabetic, and vehicle-
receiving diabetic (distilled water-receiving 
diabetic), with at least 8 rats in each group. 
Diabetes was induced by intraperitoneal 
injection of 45mg/kg (12,13) streptozotocin (STZ) 
dissolved in 0.05 M citrate buffer (14). To detect 
diabetes, the glucose levels of blood collected from 
the tail vein was measured one week after STZ 
injection by a glucometer kit (Accu-Chek). The rats 
were fasted from 8 pm to 8 am before measuring 
blood sugar (26). 
Animals with blood glucose levels of more than 
200 mg/dL were considered as diabetic (13,15). In 
order to treat neuropathic hyperalgesia, (5,10,20 
mg/kg, intraperitoneal) Angipars was used in this 
study for 2 weeks, 6 weeks after the diagnosis of 
rats diabetes. The control group (vehicle) received 
distilled water for 2 weeks from the end of the sixth 
week (16). The medications were obtained from 
Pars Pharmaceutical Company. 
Pain was assessed through the two methods of 
tail flick and hot plate. 
The tail flick test is a standard test for 
measurement of hyperalgesia. In this test, thermal 
light with an intensity of 5 is focused on the tail end 
by a tail flick device (LE7406) and the tail flick 
latency is measured from the beginning of radiating 
heat to flickering of the tail, in seconds. To prevent 
tissue damage to the tail, the maximum time of heat 
radiation was considered 10 seconds. The tail flick 
latency was measured 3 times for each animal and 
the mean of these measurements was reported as 
the latency time (TFL). There were 5 minutes 
intervals between measurements (17). 
The hot plate device (LE7106) was the other 
tool used to measure the sensitivity to pain. The 
device includes a plate of 19 cm diameter and a 
plexiglas wall of 30 cm height. The device is heated 
via electrical resistance connected to a timer and a 
thermostat. The degree was set to 52 °C. The 
thermal pain response time was measured since the 
start of the test until the animal began to lick his 
front legs or jump. The cut-off for animal reaction 
to thermal pain was considered 60 seconds (17). 
The data were presented as mean±SEM. 
Statistical difference was assessed by one-way 
ANOVA, and in case of significance, the 
differences between groups were analyzed by 
Tukey Post Hoc. P<0.05 was considered as the 
significance level. 
 
Results: 
Metabolic profile 
Plasma glucose concentrations in diabetic rats at 
the end of the first week was 287.24% more than 
the control group (P<0.0001). As can be seen in 
Table 1, the diabetic rats weighted lower than the 
controls after 8 weeks. Treatment with Angipars (5, 
10, 20 mg/kg) for 2 weeks had no significant effect 
on blood glucose levels in diabetic rats (Table 1). 
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Table 1. Body Weight and Blood Glucose Levels Before and After Intervention in all Groups 
Group (n=8) 
Weight before injection 
of STZ (g) 
Weight after intervention 
(g) 
Blood sugar before 
intervention (mg/dl) 
Blood sugar after 
intervention (mg/dl) 
Control 270±4.62 276.25±4.70 125±9.87 132.87±12.59 
Sham 260±8.16 215.57±9.54 447.14±29.97 512.85±28.92 
Vehicle 262.85±5.65 222.57±5.42 423.71±41.14 491.42±33.19 
Angipars 5mg 257.14±8.08 210±17.32 457.14±43.31 492.85±51.94 
Angipars 10mg 275.55±4.74 263.33±10.54 391.33±22.21 459.22±31.66 
Angipars 20mg 266.25±4.97 231.25±5.80 395.87±23.05 471.25±20.73 
* Data are in mean±SD 
 
 
 
Figure 1. Effect of Angipars on the reaction time to 
pain in the tail flick test 
** P<0.01 significant difference of the vehicle and sham groups with 
the controls. 
††† P<.001 significant difference of the 10 mg Angipars-receiving 
group with the vehicle and sham groups. 
 
According to the effect of Angipars on treatment 
of diabetic neuropathic hyperalgesia assessed with 
the hot plate test, it was shown that diabetes and 
high blood sugar for long time can lead to 
neuropathic hyperalgesia and reduce the response 
time to thermal pain; so that eight weeks after 
induction of diabetes in this study, the reaction time 
to thermal pain in the vehicle-receiving diabetic 
group and the sham group was significantly 
decreased compared to the control group 
(P<0.01). Intraperitoneal administration of 
Angipars at a dose of 5 and 10 mg for 2 weeks 
resulted in a significant increase in the reaction time 
to pain in STZ-induced diabetic rats compared to 
the vehicle-receiving diabetic and sham groups in 
hot plate test (P<0.01). The reaction to thermal 
pain in the 20mg Angipars group had no significant 
increase compared to the vehicle-receiving diabetic 
and sham groups (Fig. 2). 
 
 
 
 
 
 
Figure 2. Effect of Angipars on the reaction time to 
pain in the hot plate test 
** P<0.01 significant difference of the vehicle and sham groups with 
the controls. 
††† P<.001 significant difference of the 5 mg and 10 mg 
Angipars group with the vehicle and sham groups. 
 
According to the effect of Angipars on treatment 
of diabetic neuropathic hyperalgesia assessed with 
the tail flick test, it was shown that the reaction time 
to pain was significantly lower in the sham and 
vehicle groups than the controls (P<0.01). The 
reaction time to pain was significantly increased in 
the 10 mg Angipars group compared to the sham 
(P<0.01) and vehicle (P<0.001) groups, although 
the reaction time to pain in the 5mg and 20mg 
Angipars groups had no significant difference 
compared to the sham and vehicle groups, the 
reaction to pain was close to that of the control 
group (Fig. 1) 
 
Conclusion: 
In the present study, it was shown that the use of 
Angipars, after induction and proving of diabetic 
neuropathy, can reduce hyperalgesia in the test of 
response to thermal pain in diabetic animals during 
a period similar to the control condition. 
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Peripheral damage of neurons caused by 
oxidative stress can be diagnosed in more than 50% 
of people with diabetes (18). Peripheral neuropathy 
is associated with increased activity of nerve fibers 
at an early stage which leads to impairment in 
natural sensitivity of nervous system to painful 
stimuli and development of diabetic hyperalgesia 
(19). Therefore, modification of pain in these 
patients is important. Accordingly, it seems 
necessary to evaluate the treatment strategies which 
can reduce the progression of neuronal injury and 
prevent the development of hyperalgesia through 
decreasing oxidative stress and exerting anti-
oxidative effects. 
Many studies have been performed regarding 
the beneficial effects of antioxidants on performance 
and structure of peripheral nerve tissues. Podratz J 
et al. showed that antioxidants are essential for 
myelination of the dorsal root of neuronal axons 
(20). It was shown in another study that 
consumption of palm extract and melatonin, both as 
antioxidant, can reduce neuropathic hyperalgesia in 
animals with diabetes (21). 
In our study, Angipars at low- and medium-
dose increased the latency time of response to 
thermal pain in hot plate test so that the reaction 
time to pain in these groups approached to the 
control group. These results were repeated in the 
other thermal test, i.e. the tail flick test. Angipars at 
a dose of 10 mg/kg increased the latency time of 
response to thermal pain, and the reaction time to 
pain in this group was close to that of the control 
group. Therefore, it seems that the use of 10 mg/kg 
Angipars for 2 weeks, after induction of diabetic 
neuropathy, prevents development of diabetic 
hyperalgesia and increases the response time to 
pain, similar to the control group. The discussed 
effects of Angipars can help prevent diabetes-
induced hyperalgesia and increase the response time 
to thermal pain in diabetic rats due to various 
reasons. Delay in inflammatory reactions and 
angiogenesis to repair nerve on the other hand, can 
affect the nerve conduction velocity as well as the 
time of response to pain induced by diabetes. 
Several studies have shown that Angipars can 
completely repair and close wound gap, and some 
studies reported an enhancement in wound healing. 
Recent studies using different methods have shown 
that the extract of this drug, with hydrocortisone-
like and anti-inflammatory effects, improves blood 
circulation in venules of leg ulcers in diabetic 
patients (9). Larijani et al. showed that Angipars 
can increase the overall blood flow of tissue and 
hence increase tissue oxygenation due to 
angiogenesis (22). Angipars is effective through 
reducing inflammation and oxidative damages on 
periodontium (24,25). In addition, intravenous 
administration of  Angipars can be an effective 
treatment for patients with severe gastric wounds 
(25). Angipars herbal medicine has a positive effect 
on sperm count in the diabetic animals especially 
when used in combination with insulin (26). 
In summary, it seems that the use of Angipars 
after proving the neuropathy can be effective in the 
treatment of diabetes-induced destruction of 
neurons, and can approximate the reduced 
threshold of pain in diabetic neuropathy to norma. 
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های صحرایی نر دیابتی شده با داروی آنژیپارس بر آستانه درد نوروپاتی در موش اثر
 ترپتوزوتوسیناس
 
  3 محمد شعبانیدکتر   2 اندانا جعفریم  1 آبادیناصر زنگیدکتر 
استادیار گروه  7 مرکز تحقیقات فارماسیوتیکس،  دانشجوی کارشناسی ارشد گروه زیست شناسی،  2 مرکز تحقیقات  علوم اعصاب،  ، استادیار گروه نورولوژی 5
 انشگاه علوم پزشکی کرمان علوم اعصاب،  مرکز تحقیقات علوم اعصاب،   د
 257-257 صفحات  94هر و آبان م چهارم شماره   نوزدهممجله پزشکی هرمزگان  سال 
 دهچکي
ها در تسکین درد نوروپاتیک اکسیدانثیر آنتیأباشد. بررسی تترین علل درگیری اعصاب محیطی میدیابت شایع :مقدمه
در درمان هیپرآلژزی نوروپاتیک در داروهای آنژیپارس  بررسی اثر ،لعه. هدف از انجام این مطاتدیابتی حائز اهمیت اس
 ) بود.ZTS( های صحرایی نر دیابتی شده با تزریق تک دوز استرپتوزوتوسینموش
گرمی انجام شد.  512-557در محدوده وزنی  yelwad euqarpSموش نژاد  سر 51مطالعه بر روی  :روش کار
موش  9(حداقل  حلال تقسیم شدند و)، دیابتی دریافت کننده آنژیپارس mahs( ترل، شمهای صحرایی به چهار گرو: کنموش
به ازای هر کیلوگرم وزن بدن استرپتوزوتوسین حل شده در بافر  19 gm القای دیابت با تزریق داخل صفاقی. گروه) در هر
 52، 55، 1هفته آنژیپارس ( 2ی به مدت های گروه دیابتها، موشدیابتی شدن موش ییدأانجام شد. پس از ت M50.0سیترات 
های کنترل و موش، گرم به ازای هر کیلوگرم وزن بدن، داخل صفاقی) و حلال دریافت کردند. در انتهای هفته هشتممیلی
جهت بررسی تفاوت آماری از انالیز واریانس  قرار گرفتند. kcilF liaTو  etalP toH هایتیمار شده تحت بررسی آزمون
 داری در نظر گرفته شد.به عنوان سطح معنی <P5/15 استفاده شد و یک طرفه
زمان پاسخ به هیپرآلژزی حرارتی در گروه حلال و شم نسبت به گروه کنترل کاهش یافت.  ،در انتهای هفته هشتم :نتایج
toHآنژیپارس باعث افزایش زمان پاسخ به هیپرآلژزی حرارتی نسبت به گروه حلال و شم در آزمون  55و  1 gm دوز
باعث افزایش زمان پاسخ به درد در زمانی شبیه به گروه کنترل   kilF liaTانژیپارس در آزمون  55gm شد. دوز  etalP
 شد.
هیپرآلژزی  اکسیدان قادر به کاهشنتیآوان یک به عنمصرف انژیپارس این مطالعه نشان داد که  :گيرینتيجه
 .باشدمینوروپاتیک در حیوانات مبتلا به دیابت 
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